Home Featured Page 182

Featured

Latest

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Psychedelic Drugs Market Reaches US$6330.0 Mn by 2026 from US$3210.0 Mn...

Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

Numinus to Host Q3 2022 Results Conference Call on July 14,...

Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate...

FILAMENT HEALTH ANNOUNCES SIXTH PATENT ISSUANCE

Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel...

BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research...

PT334 – Prof. David Nutt – The Human Brain, Addiction, and...

PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

Psychedelic Bulletin #109 – California Decrim. Back on the Agenda; Reanalysis...

EDITOR PICKS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Who Gets to Heal?

Psychedelic Drugs Market Reaches US$6330.0 Mn by 2026 from US$3210.0 Mn...

Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

Numinus to Host Q3 2022 Results Conference Call on July 14,...

Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate...

FILAMENT HEALTH ANNOUNCES SIXTH PATENT ISSUANCE

Mindset Pharma Receives Allowance for Patent Application Covering its Short-Duration Novel...

BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research...

PT334 – Prof. David Nutt – The Human Brain, Addiction, and...

PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch

Psychedelic Bulletin #109 – California Decrim. Back on the Agenda; Reanalysis...

EDITOR PICKS

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY